BRPI0607882A2 - método e composição para tratamento de diabetes - Google Patents

método e composição para tratamento de diabetes

Info

Publication number
BRPI0607882A2
BRPI0607882A2 BRPI0607882-6A BRPI0607882A BRPI0607882A2 BR PI0607882 A2 BRPI0607882 A2 BR PI0607882A2 BR PI0607882 A BRPI0607882 A BR PI0607882A BR PI0607882 A2 BRPI0607882 A2 BR PI0607882A2
Authority
BR
Brazil
Prior art keywords
composition
treating diabetes
cells
tvemf
compositions
Prior art date
Application number
BRPI0607882-6A
Other languages
English (en)
Inventor
Donnie Rudd
David Wolf
Original Assignee
Regenetech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenetech Inc filed Critical Regenetech Inc
Publication of BRPI0607882A2 publication Critical patent/BRPI0607882A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MéTODO E COMPOSIçãO PARA TRATAMENTO DE DIABETES. A presente invenção está voltada para a expansão por TVEMF de células tronco de sangue de mamífero, de preferência células CD34+/CD38-, para composições resultantes das células expandidas por TVEMF, e para um método de tratamento de doenças ou reparo de tecido com as composições.
BRPI0607882-6A 2005-02-28 2006-02-27 método e composição para tratamento de diabetes BRPI0607882A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65755305P 2005-02-28 2005-02-28
PCT/US2006/006817 WO2006093858A2 (en) 2005-02-28 2006-02-27 Method and composition for treating diabetes

Publications (1)

Publication Number Publication Date
BRPI0607882A2 true BRPI0607882A2 (pt) 2009-11-24

Family

ID=36941684

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607882-6A BRPI0607882A2 (pt) 2005-02-28 2006-02-27 método e composição para tratamento de diabetes

Country Status (11)

Country Link
US (1) US20060193838A1 (pt)
EP (1) EP1855535A4 (pt)
JP (1) JP2008531695A (pt)
KR (1) KR20070111533A (pt)
CN (1) CN101188941A (pt)
BR (1) BRPI0607882A2 (pt)
CA (1) CA2599275A1 (pt)
EA (1) EA200701826A1 (pt)
IL (1) IL185555A0 (pt)
MX (1) MX2007010531A (pt)
WO (1) WO2006093858A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060193839A1 (en) * 2005-02-28 2006-08-31 Donnie Rudd Method of providing readily available cellular material derived from peripheral blood, and a composition thereof
WO2007092222A2 (en) * 2006-02-02 2007-08-16 Regenetech, Inc. Method of characterizing a biologically active compound
US20090081752A1 (en) * 2007-09-24 2009-03-26 Dennis Robert G Bioreactor, kit and method of using same
US8993231B2 (en) * 2008-03-18 2015-03-31 Marshall University Research Corporation Methods for stem cell production and therapy
ES2747951T3 (es) 2013-10-24 2020-03-12 Ospedale San Raffaele Srl Método
US10202598B2 (en) * 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US9410143B1 (en) 2014-06-10 2016-08-09 Endonovo Therapeutics, Inc. Biological molecules produced by electromagnetically stimulating living mammalian cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5728581A (en) * 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
US6962698B1 (en) * 1998-02-17 2005-11-08 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
US6485963B1 (en) * 2000-06-02 2002-11-26 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Growth stimulation of biological cells and tissue by electromagnetic fields and uses thereof
WO2002044346A2 (de) * 2000-11-29 2002-06-06 William Rader Stammzellen, verfahren zu deren expansion in vitro sowie deren verwendung
US20040136969A1 (en) * 2002-10-02 2004-07-15 New York University Adult bone marrow derived stem cells
DE10362002B4 (de) * 2003-06-23 2006-10-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Adulte pluripotente Stammzellen
US20060205071A1 (en) * 2003-07-17 2006-09-14 Gamida-Cell Ltd. Methods for ex-vivo expanding stem/progenitor cells
US20050084962A1 (en) * 2003-08-20 2005-04-21 Bruce Simon Methods of treatment using electromagnetic field stimulated stem cells
US20080057042A1 (en) * 2005-01-27 2008-03-06 Donnie Rudd Method of providing readily available cellular material derived from cord blood, and a composition thereof
US20080050348A1 (en) * 2006-02-27 2008-02-28 Donnie Rudd Method and composition for repairing heart tissue
US20080075700A1 (en) * 2006-02-27 2008-03-27 Wolf David A Method and composition for treating diabetes

Also Published As

Publication number Publication date
MX2007010531A (es) 2007-11-08
KR20070111533A (ko) 2007-11-21
CN101188941A (zh) 2008-05-28
WO2006093858A2 (en) 2006-09-08
IL185555A0 (en) 2009-02-11
EP1855535A4 (en) 2009-10-14
JP2008531695A (ja) 2008-08-14
EA200701826A1 (ru) 2008-04-28
US20060193838A1 (en) 2006-08-31
EP1855535A2 (en) 2007-11-21
CA2599275A1 (en) 2006-09-08
WO2006093858A3 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
BRPI0607883A2 (pt) método para obter material celular prontamente disponìvel derivado de sangue periférico e uma composição do referido material celular
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BRPI0921999B8 (pt) uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA200701390A1 (ru) Способ получения легкодоступного клеточного материала из пуповинной крови и композиция на его основе
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
MX2009013970A (es) Gel de fibrina para la liberacion controlada del factor de crecimiento derivado de plaqueta (pdgf) y sus usos.
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
IL186741A0 (en) Optical probe for delivery of light
MX2010007846A (es) Fabricación de enzimas sulfatasa lisosomal humana altamente fosforilada, activa y usos de las mismas.
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
WO2007092622A3 (en) Compositions and methods for treating bone
CO6660423A2 (es) Composiciones y métodos para tratar la enfermedad de gaucher
MX2011011768A (es) Composiciones y metodos de uso para moleculas de enlace a dickkopf-1 o dickkopf-4 o a ambos.
BR112012013329A2 (pt) composição oral e método para o tratamento de uma doença ou condição do tecido mole da cavidade oral
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
BRPI0608277A2 (pt) método e composição para o reparo de tecidos do coração
BRPI0513317A (pt) ciclosporinas para tratar doença de alzheimer
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
CL2008002480A1 (es) Compuestos derivados de 3-(4-aminofenil)-metil-4-hidroxi-5-amino-tiopirano, inhibidores de beta-secretasa bace; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica, y su uso en el tratamiento de trastornos neurologicos o vaaculares, tal como la enfermedad de alzheimer, sindrome de down y deterioro de la memoria.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 5A, 6A, 7A E 8A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2260 DE 29/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A, 13A E 14A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.